Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;204(5):1908-1912.
doi: 10.1111/bjh.19321. Epub 2024 Feb 7.

Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention

Julia Trepl  1 , Chloé Pasin  2   3 , Dominik Schneidawind  1 , Nicolas J Mueller  3 , Markus G Manz  1 , Andriyana K Bankova  1   4 , Irene A Abela  2   3
Affiliations

Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention

Julia Trepl et al. Br J Haematol. 2024 May.

Abstract

Allogeneic haematopoietic cell transplantation (allo-HCT) recipients exhibit an increased risk of COVID-19, particularly in the early post-transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS-CoV-2 infection in allo-HCT recipients who received tixagevimab/cilgavimab pre-exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS-CoV-2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS-CoV-2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID-19.

Keywords: COVID‐19; SARS‐CoV‐2; monoclonal antibodies; risk factors; stem cell transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
    1. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID‐19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143.
    1. Huang A, Cicin‐Sain C, Pasin C, Epp S, Audige A, Muller NJ, et al. Antibody response to SARS‐CoV‐2 vaccination in patients following allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:214.e1–214.e11.
    1. Bankova AK, Pasin C, Huang A, Cicin‐Sain C, Epp S, Audige A, et al. Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. Br J Haematol. 2023;201(1):58–63.
    1. Maillard A, Redjoul R, Klemencie M, Labussiere Wallet H, Le Bourgeois A, D'Aveni M, et al. Antibody response after 2 and 3 doses of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood. 2022;139(1):134–137.

Substances

LinkOut - more resources